Romosozumab and Cardiovascular Safety: Bridging the Gap between Clinical Trials and Real-World Evidence Authors: Beom-Jun Kim Published: 2026 The introduction of romosozumab, a monoclonal antibody targeting sclerostin, marked a paradigm shift in the management of severe postmenopausal osteoporosis. By simultaneously stimulating bone formation and inhibiting bone resorption, romosozumab provides rapid gains in bone mineral density and substantial fracture risk reduction [1]. Nevertheless, uncertainty regarding cardiovascular safety has continued to shadow its clinical application. Whereas the placebo-controlled FRAME trial demonstrated a reassuring cardiovascular safety profile [1], the active-controlled ARCH trial reported a numerical imbalance in major adverse cardiovascular events (MACE) during the first year of treatment compared with alendronate [2]. This unexpected signal prompted regulatory agencies worldwide to issue boxed warnings advising against the use of romosozumab in patients who experienced myocardial infarction or stroke within the preceding year. Since the publication of the ARCH trial, a critical question has focused the attention of the bone research community: whether the observed cardiovascular signal reflects true biological cardiotoxicity induced by sclerostin inhibition or instead represents an artifact of trial design potentially driven by the cardioprotective effects of the active comparator, alendronate [3]. Basic and translational research has largely failed to identify a plausible biological mechanism supporting romosozumab-induced cardiotoxicity. Although sclerostin is predominantly expressed by osteocytes, its role in the vasculature remains uncertain. Histological evaluations of advanced human atherosclerotic plaques have shown that sclerostin is not expressed in regions critical to plaque stability, such as the fibrous cap and endothelium [4]. Furthermore, studies in nonclinical animal models of atherosclerosis, including ovariectomized and apolipoprotein E knockout mice, as well as clinical observations in patients with sclerosteosis, a genetic disease characterized by lifelong sclerostin deficiency, have demonstrated no evidence of premature cardiovascular disease [5,6]. Given the absence of a clear biological mechanism, the medical community has increasingly turned to real-world evidence to contextualize the ARCH findings. Reassuringly, a growing body of global post-marketing data has consistently demonstrated a neutral cardiovascular safety profile for romosozumab. Large-scale Japanese cohort studies using inverse probability of treatment weighting and analyses from global federated health networks have shown that the risk of MACE among patients receiving romosozumab is comparable to, or numerically lower than, that among patients receiving teriparatide or parathyroid hormone analogs [7,8]. Longitudinal analyses from Israel further suggest that MACE incidence during romosozumab treatment is primarily driven by pre-existing cardiovascular risk factors rather than by the medication itself [9]. In addition, recent United States Medicare data demonstrated that, under current labeling recommendations, the absolute proportion of romosozumab initiators with a recent myocardial infarction or stroke remained exceptionally low (0.1% to 0.4%), suggesting effective real-world patient selection. In this context, the study by Ahn et al. [10], published in the current issue of Endocrinology and Metabolism (EnM), makes an important contribution to the literature. The authors used the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) across three major tertiary hospitals in South Korea to evaluate the cardiovascular safety of romosozumab in a real-world East Asian population. A notable strength of this multicenter cohort study is the careful selection of the active comparator. The investigators achieved clinical equipoise by comparing romosozumab with denosumab, a potent antiresorptive agent with an established neutral cardiovascular profile [11]. After rigorous 1:1 large-scale propensity score matching to adjust for baseline demographics, comorbidities, and medication histories, the study evaluated both 1- and 3-year outcomes [10]. The findings are reassuring. Ahn et al. [10] reported no statistically significant difference in the incidence of MACE between the romosozumab and denosumab groups at 1 year (adjusted hazard ratio [aHR], 1.42; 95% confidence interval [CI], 0.64 to 3.19) or 3 years (aHR, 1.51; 95% CI, 0.79 to 2.88). Similarly, the risk of all cardiovascular adverse events, including heart failure and peripheral artery disease, was comparable between the two cohorts. Subgroup analyses yielded consistent findings, with no significant differences in cardiovascular risk according to sex or age group [10]. These findings carry important clinical implications. First, they further support the hypothesis that the cardiovascular imbalance observed in the ARCH trial may not reflect a direct cardiotoxic effect of romosozumab but instead may represent an artifact related to the active comparator. Second, the findings suggest that, when prescribed in accordance with current labeling recommendations that exclude patients with recent acute cardiovascular events, romosozumab may be used without an apparent excess risk of MACE in appropriately selected patients [10]. Several aspects of the study deserve particular emphasis. The use of a distributed research network (OASIS) operating on the OMOP-CDM framework enhances transparency, reproducibility, and external generalizability and provides a valuable model for future real-world pharmacoepidemiological research in osteoporosis [10,12]. At the same time, the inherent limitations of observational research must be acknowledged. The modest number of adjudicated cardiovascular events, the possibility of residual confounding despite rigorous propensity score matching, and the tendency to avoid prescribing romosozumab to higher-risk patients in routine clinical practice collectively limit the strength of the conclusions that can be drawn. Osteoporosis remains a silent epidemic, and reluctance to prescribe highly effective osteoanabolic therapies because of unresolved safety concerns leaves vulnerable patients exposed to the devastating consequences of fragility fractures. The evidence presented by Ahn et al. [10] in EnM provides reassurance that, when used in accordance with current guidelines, romosozumab does not appear to confer a meaningful excess cardiovascular risk relative to denosumab. Nevertheless, the absence of a statistically significant signal in this and other real-world cohorts should not be interpreted as definitive proof of cardiovascular safety. Continued post-marketing surveillance and longer-term comparative studies will be essential before the uncertainty surrounding ARCH can be fully resolved. For now, however, this study represents an important step toward an era in which the substantial anti-fracture benefits of romosozumab may be more confidently applied in the patients most likely to benefit. Footnotes CONFLICTS OF INTEREST Beom-Jun Kim is a deputy editor of the journal. But he was not involved in the peer reviewer selection, evaluation, or decision process of this article. REFERENCES